Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 5,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Stress, Sleep, Craving, Well Being
Interventions: Ashwagandha, Placebo; Dietary Supplement · Other
Lead sponsor: University of Colorado, Colorado Springs; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Peanut Allergy
Interventions: AR101 powder provided in capsules, Placebo powder provided in capsules; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 26 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Hemet, California • DeBary, Florida • Venice, Florida + 9 more

Conditions: Diabetic Neuropathies
Interventions: Fish Oil Concentrate, 1000 Mg Oral Capsule, Salsalate Oral Tablet; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Iowa City, Iowa • Portland, Oregon

Conditions: Myelodysplastic Syndromes
Interventions: Oral rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 10
States / cities: Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Chronic Hepatitis C
Interventions: Daclatasvir, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more

Conditions: Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
Interventions: AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg), Rosuvastatin 10 mg tablet.; Drug
Lead sponsor: Advenchen Laboratories, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 14 more

Conditions: Healthy
Interventions: Poziotinib, Itraconazole, Phenytoin, Paroxetine; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Breast Cancer, Non-small Lung Cancer
Interventions: Docetaxel, GDC-0032, Paclitaxel; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 10
States / cities: Tampa, Florida • Boston, Massachusetts • Detroit, Michigan + 5 more

Conditions: Hepatitis C Virus
Interventions: Daclatasvir, Simeprevir, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: San Francisco, California • Indianapolis, Indiana • Lutherville, Maryland + 3 more

Conditions: Healthy
Interventions: Opevesostat, Prednisone, Fludrocortisone acetate, Itraconazole; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Aging, Inflammaging, Metabolic Health, Quercetin, Coenzyme Q10
Interventions: Quercetin (dietary supplement), Coenzyme Q10, Rice Flour; Dietary Supplement
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hyperlipidemia, NAFLD
Interventions: VK2809, Placebo; Drug
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 19
States / cities: Chandler, Arizona • Garden Grove, California • Los Angeles, California + 13 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: QVA149, QAB149, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 47
States / cities: Vestavia Hills, Alabama • Huntington Beach, California • Lakewood, California + 43 more

Conditions: Hepatic Impairment
Interventions: IPI-145; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 2 Diabetes
Interventions: Mitoglitazone, Pioglitazone, Placebo; Drug
Lead sponsor: Metabolic Solutions Development Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Chino, California + 21 more

Conditions: Myelodysplastic Syndrome
Interventions: Revlimid (Lenalidomide); Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimers Disease
Interventions: CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum; Biological · Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 78
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more

Conditions: Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia Type 17, ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1
Interventions: CAD-1883, Placebos; Drug
Lead sponsor: Cadent Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Long Beach, California • Los Angeles, California • Aurora, Colorado + 3 more

Conditions: Fecal Incontinence
Interventions: Loperamide, Placebo, Anal exercises with biofeedback, Usual Care; Drug · Behavioral
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 6 more

Conditions: Healthy
Interventions: Lansoprazole, Prevacid®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Cognitive, Mood and Cognitive Performance, Sleep Deprivation, Executive Function (Cognition), Fatigue
Interventions: Alpha Brain proprietary cognitive dietary supplement, Alpha Brain 2.0 proprietary cognitive dietary supplement, Controlled Placebo; Dietary Supplement
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 20 Years to 59 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Depression
Interventions: 2:1 EPA/DHA, High EPA, Placebo; Drug · Other
Lead sponsor: Wei Jiang; Other
Eligibility: 21 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: ADHD
Interventions: Centanafadine, Methylphenidate, Lisdexamfetamine; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

The Impact of Ashwagandha on Perceived Stress, Sleep and Food Cravings in College Students

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

Revlimid in Transfusion Dependent Patients

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Study of CAD-1883 for Spinocerebellar Ataxia

Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)

Lansoprazole 30 mg DR Capsule Replicate Food Study

The Acute Effects of Onnit Alpha Brain on Cognition and Mood States

Omega 3 for Treatment of Depression in Patients With Heart Failure

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body